Non-Patent Exclusivity Period Proposed For Biologics In Face Of Follow-Ons
A period of non-patent exclusivity for biologic products is necessary to preserve incentives for innovation in the face of follow-on biologics, attorneys argue in an article in the March/April issue of Health Affairs
You may also be interested in...
Manufacturers seeking regulatory approval of a follow-on biologic in the EU may be able to forgo clinical comparability trials under certain conditions, according to final guidelines on similar biologics issued by the European Medicines Agency March 8
The European Medicines Agency's endorsement of Sandoz' human growth hormone Omnitrope could put further pressure on U.S. regulators to develop an approval pathway for follow-on biologics
A Supreme Court ruling that extends "Bolar Amendment" protection to preclinical research on new drug candidates could aid the development of follow-on biologics, attorney Kathleen Madden Williams (Palmer & Dodge) said